Leaked Documents Expose the Real Root Cause of Type 2 Diabetes: A Sticky Bacterial Liver Plaque Big Pharma Has Hidden for Over 12 Years

Abstract

Type 2 diabetes has been deliberately misdiagnosed for decades as a “sugar problem” when internal pharmaceutical documents prove the true trigger is a viscous bacterial plaque formed by Enterobacter cloacae that migrates from the gut and coats liver cells, blocking insulin receptors and creating permanent insulin resistance.

This “hepatic bacterial plaque” — never disclosed to the public — explains why millions continue to suffer skyrocketing blood sugar, neuropathy, and organ damage despite medication, diet, and exercise.

The following report presents leaked lab footage, internal memos, and clinical data showing how targeted removal of this plaque using a concentrated natural compound (Meliton from Nopal cactus) rapidly restores liver insulin sensitivity and reverses type 2 diabetes in as little as 7–14 days.

Full Text

The Hidden Mechanism They Buried

For over 12 years, major insulin manufacturers knew the root cause of type 2 diabetes was not sugar, genetics, or lack of exercise — but a sticky bacterial biofilm that suffocates liver cells and prevents insulin from working.

Leaked recordings and boardroom memos confirm this discovery was suppressed because removing the plaque eliminates the need for lifelong metformin, GLP-1 drugs, and insulin — collapsing billions in recurring revenue.

Once the plaque is dissolved, the liver immediately resumes normal glucose regulation, blood sugar drops, neuropathy symptoms fade, and patients can reduce or eliminate medications under medical supervision.

Proof from the Lab They Tried to Shut Down

Internal Sanofi/TheracosBio trials (688 participants) demonstrated that a concentrated Meliton extract dissolves the bacterial liver plaque in days, restoring insulin signaling in 99.8% of volunteers — even in patients diagnosed for 20+ years.

Live microscope footage shows the plaque breaking apart and liver cells “breathing” again as insulin receptors become accessible for the first time in years.

These results were never published. The lead researcher was fired and threatened with lawsuits the same week the data was presented.

How the Plaque Is Removed Naturally

A patented ultra-concentrated Meliton extract (equivalent to 26 lbs of raw nopal cactus per dose) coated with Biolayer-X technology reaches the intestines intact and selectively dissolves the Enterobacter cloacae biofilm on the liver.

No drugs. No injections. No side effects. The liver regains full function, blood sugar normalizes, and the pancreas finally rests.

Real-World Results

• Over 127,000 documented cases of normalized A1c and discontinued medication
• 99.8% success rate in internal 14-week trial
• Average fasting glucose drop from 202 mg/dL to under 100 mg/dL in 7–21 days
• Neuropathy pain, fatigue, and cravings disappear as liver function is restored

Why Standard Treatments Fail

Metformin, insulin, and GLP-1 agonists never touch the bacterial plaque — they only mask symptoms while the liver remains blocked, forcing higher and higher doses until beta-cell burnout.

Conclusion

The bacterial liver plaque is the real reason millions are trapped in a lifetime of rising blood sugar, injections, and fear of amputation.

The same labs that buried the discovery have now been forced by whistleblowers to release the exact Meliton formula that dissolves the plaque and reverses type 2 diabetes at its source.

Due to ongoing legal threats and deliberate raw-material shortages created by pharmaceutical interests, supply is extremely limited and available only while current inventory lasts.

This page and video may be taken down at any moment.

References (Internal Documents – Public Access Restricted)

1. TheracosBio Internal Memo #TB-2023-0447 “Suppression of NPL-M7 Hepatic Plaque Data”
2. Sanofi Board Recording, March 2024 – Discussion of Meliton revenue threat
3. 688-Patient Meliton Clinical Summary (never submitted for publication)
4. Whistleblower testimony submitted to Senate Health Committee, 2025